Skip to content

Prof Sarah Tabrizi

UCL Institute of Neurology

3.06
Institute of Neurology
UCL Queen Square
London
England
WC1N 3BG

s.tabrizi@ucl.ac.uk

Tel: 0203 448 4053

Fax: 0207 611 0129

Biography

Sarah leads a synergistic research programme in neurodegeneration from basic cellular mechanisms of protein misfolding (using prions as a model tool) to translational clinical research. Sarah has had a major research interest in Huntington’s disease (HD) since her PhD, and Sarah’s team is spearheading a major effort to develop and test new disease-modifying therapies for HD. Her work leading TRACK-HD, an international study to understand the neurobiology of HD, has already identified biomarkers of disease progression that track the earliest phase of the neurodegenerative disease process in clinically-well individuals who carry the HD expansion mutation and those with early disease symptoms. Her work at the laboratory level aims to translate these approaches to patients within the next few years. Sarah also identified a key role for the innate immune system in the pathogenesis of HD that has given rise to important new avenues for research into biomarkers and disease-modifying therapies for HD. Sarah’s research programme is translating HD research directly from the lab to patients with a programme that is ultimately aimed at preventing the neurodegenerative disease process itself.

IRIS profile

Available Projects:

Novel Imaging Biomarker Development for Detecting Pre-manifest Changes in Huntington’s Disease with Advanced Diffusion MRI

Development of Novel Structural Connectivity Measures for Application to Multiple Time-point Imaging Data in Huntington’s Disease Patients